Histosonics ( www.histosonics.com ), the non-invasive Edison® Histotripsy System and innovative sound wave therapy, is a Medicare – The Centers for Medicaid Services (CMS) announced a new subsidy of $17,500 for histotripsy surgery for liver tumors. In the November 2023 rulemaking process, CMS will utilize submission data from the #HOPE4LIVER trial in the United States to identify non-thermal acoustic energy-induced Increased subsidies for outpatient surgery involving liver cell tissue destruction and image guidance to a new national average rate of $17,500. This will support hospitals and doctors who perform non-invasive histotripsy surgery as an outpatient procedure. Patients who require hospitalization will be eligible for the traditional Diagnosis-Related Group (DRG) subsidy.
Mike Blue, president and CEO of Histosonics, said, “CMS’ increased subsidy for Histotripsy liver surgery increases the availability of Histotripsy to Medicare patients. Thank you for facilitating access for Medicare patients to groundbreaking devices like this. Advances like this are significant.” HistoSonics’ Edison Histotripsy System combines advanced image processing and proprietary software to provide patient-specific treatment and uses Histotripsy technology to mechanically disrupt target tissue at the cellular level. Histotripsy has been shown to be safe and effective in destroying targeted liver tumors, including unresectable liver tumors, and was recently approved by the FDA for the non-invasive treatment of liver tumors using the Edison system. I also got it. This technique uses non-thermal, mechanically focused ultrasound waves.
Additionally, the American Medical Association (AMA) has issued a new Category III CPT code for histotripsy of kidney tissue. This is so important that patients and doctors can receive the first automated external beam radiation therapy, which uses acoustic energy to mechanically destroy diseased kidney tissue without the use of incisions, ionizing radiation, or heat. provided to you. The new CPT code will go into effect in the U.S. on July 1, 2024, and from that date on, healthcare providers across the U.S. will be able to administer histotripsy to patients as part of a clinical trial sponsored by Histosonics called the #HOPE4KIDNEY trial. This code can be used when performing surgery.
CPT codes are assigned by the American Medical Association (AMA) CPT® Editorial Panel and are widely used by government payers, including Medicare and Medicaid, and commercial health insurance. These codes are used to describe medical services and procedures and provide information for billing purposes. The issuance of this new code marks an important milestone in allowing U.S. hospitals to bill directly for related services. When kidney histotripsy receives FDA marketing approval, this new code will allow patients and physicians to utilize histotripsy as a non-invasive kidney tissue treatment option, making it easier to treat histotripsy than traditional treatments. Potential complications such as bleeding, infection, and pain associated with surgery can be avoided.
On January 1, 2024, a new Category III CPT code, X201T, will be issued for histotripsy (i.e., non-thermal ablation with acoustic energy) of kidney tissue.
“Achieving this CPT code for kidney marks a significant milestone in our progress to bring histotripsy into the clinical setting. This allows us to use histotripsy to destroy specific kidney tissue. “This will enable us to collect data at the time of the trial, streamline the process with payers, and provide broader access to the many patients who could benefit from Histotripsy’s unique capabilities,” Blue added. I did.
The Edison system is being studied for use in the kidneys and is sold in the United States only for the specific use of destroying liver tumors.
About Histosonics
HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary acoustic beam therapies. The company leverages the science of histotripsy, an innovative treatment that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors. The company is currently working to commercialize the Edison system for liver treatment in the United States and select global markets, and is expanding the range of applications of histotripsy to other organs such as the kidney and pancreas. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Michigan.
Source link : https://www.businesswire.com/
